metalloproteinase

(redirected from Metalloproteases)
Also found in: Dictionary.

me·tal·lo·pro·tein·ase

(met'a-lō-prō'tēn-āz),
A family of protein-hydrolyzing endopeptidases that contain zinc ions as part of the active structure.

me·tal·lo·pro·tein·ase

(mĕ-tal'ō-prō'tēn-ās)
A family of protein-hydrolyzing endopeptidases that contain zinc ions as part of the active structure.
References in periodicals archive ?
Xeglyze Lotion, a topical formulation containing abametapir, an inhibitor of metalloproteases, has confirmed both ovicidal and lousicidal activity and provides the potential for a more effective treatment using only a single application.
The NDSU Core Biology Facility was created by the Center for Protease Research COBRE program in 2003 to aid in the in vitro testing of inhibitors of matrix metalloproteases and histone deacetylases.
Hatchtech's Xeglyze Lotion, a topical formulation containing abametapir; an inhibitor of metalloproteases, has demonstrated both ovicidal and lousicidal activity and offers the potential for a more effective treatment using only a single application.
Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease.
Gallibacterium anatis-secreted metalloproteases degrade chicken IgG.
iNOS can also down regulate the synthesis of Tissue Inhibitors of Matrix Metalloproteases (TIMP).
Distinct roles of matrix metalloproteases in the early and late-phase development of neuropathic pain.
After the rapid expansion of the use of monoclonal antibodies and various synthetic inhibitors directed against matrix metalloproteases or protein kinases, natural products are regaining attention in the oncology field.
In particular, cathepsin B, matrix metalloproteases, and furin-related PCSK1 are likely to be expressed on the surface of macrophages and recognize the hallmark residues remaining or acquired in FIPV S1/S2 cleavage site (30).
Grape seed proanthocyanidins were shown to reduce the invasion potential of pancreatic cancer cells by beneficially altering the gene expression of matrix metalloproteases, according to a study reported in the journal Pancreas.
The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis.
Moreover, antiangiogenic drugs used in the clinic are centered on the blockade of the VEGF-signaling pathway, whereas VEGF-independent angiogenic factors such as fibroblast growth factor, angiopoietins, placental growth factor (PlGF), matrix metalloproteases (MMPs), and ECM molecules are worth considering (6, 13).